Get the Stockscreener App
69.48
0.01%
0.005
Pre-market:
70.90
1.415
+2.04%
Belite Bio Inc Adr Stock (BLTE) Latest News
Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics - The Globe and Mail
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 ... - The Bakersfield Californian
Biotech Pioneer Belite Bio Unveils Q4 and 2024 Performance: Key Retinal Disease Updates Coming March 17 - StockTitan
Is Meta Platforms Stock a Buy, Sell, or Hold Ahead of Llama 4 Launch? - The Globe and Mail
Parkland Reports Fourth Quarter and Year-End 2024 Results; Initiates Review of Strategic Alternatives - The Globe and Mail
Darwin CX Expands Internationally, Aiming to Tackle Global Publishing Challenges with Locally Tailored Solutions - The Globe and Mail
Can Belite Bio's Retinal Disease Treatments Impress Investors at Upcoming Leerink Conference? - StockTitan
2 Large-Cap Stocks with Exciting Potential and 1 to Avoid - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Shares Gap UpShould You Buy? - MarketBeat
Promising Phase 3 Results for Belite Bio’s Tinlarebant in Stargardt Disease Boost Buy Rating - TipRanks
Belite Bio’s Phase 3 Trial for Stargardt Disease Drug Advances - TipRanks
Can Belite Bio's Tinlarebant Become First Treatment for Stargardt Disease? Phase 3 Data Shows Promise - StockTitan
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 9.2% in January - MarketBeat
Belite Bio (NASDAQ:BLTE) Stock Price Up 7.8%Should You Buy? - MarketBeat
Belite Bio (NASDAQ:BLTE) Shares Down 4.7%Time to Sell? - MarketBeat
Advisors Preferred LLC Purchases New Shares in Belite Bio, Inc (NASDAQ:BLTE) - Armenian Reporter
Why Are Cloudflare (NET) Shares Soaring Today - The Globe and Mail
Belite Bio Announces $15 Million Direct Offering to Enhance Financial Position - TipRanks
BLTEBelite Bio, Inc Latest Stock News & Market Updates - StockTitan
Sangoma Announces Second Quarter Fiscal 2025 Results - The Globe and Mail
Why Oklo Stock Jumped 96% in January - The Globe and Mail
Belite Bio Raises Fresh Capital: $30M Total Potential as Clinical Programs Advance - StockTitan
Belite Bio Announces Registered Direct Offering of $15 Million - GlobeNewswire Inc.
Flow Beverage Corp. Adds José Bautista as Strategic Advisor and Closes Second Tranche of Private Placement of Convertible Debenture Units - The Globe and Mail
Why Dominion Energy Stock Was Falling Today - The Globe and Mail
Leerink Partnrs Increases Earnings Estimates for Belite Bio - MarketBeat
Belite Bio, Inc (NASDAQ:BLTE) Stake Increased by JPMorgan Chase & Co. - MarketBeat
Stargardt Disease Market Growth to Accelerate in Forecast Period (2024-2034) | estimates DelveInsight - openPR
Where Will Nvidia Stock Be in 3 Years? - The Globe and Mail
Apple Stock Is Off Its Recent Highs, But Is It Poised to Rise Again? - The Globe and Mail
Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Decreases By 60.3% - MarketBeat
Bitcoin: Buy the Dip? - The Globe and Mail
JPMorgan Chase & Co. Grows Stock Holdings in Belite Bio, Inc (NASDAQ:BLTE) - Defense World
Is Coffee Moving to Even Higher Highs? - The Globe and Mail
Charter (CHTR) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Are These Renewable Energy Stocks in Trouble, or Are They Ultra-Cheap Buys? - The Globe and Mail
The Ultimate Growth Stock to Buy With $1,000 Right Now - The Globe and Mail
Rigetti CEO Responds to Jensen Huang and Mark Zuckerberg on the Future of Quantum Computing - The Globe and Mail
Avoid the Trap: 3 High-yield Dividend Stocks With Safe Payouts - The Globe and Mail
2 Artificial Intelligence Stocks You Can Buy and Hold for the Next Decade - The Globe and Mail
4 Soaring Stocks I'd Buy Now With No Hesitation - The Globe and Mail
Analysts Predict 1,250% Upside for This ‘Strong Buy’ Quantum Computing Stock in 2025... But Investors Should Stay Away - The Globe and Mail
XFRA : ICFFRENDE DER HANDELSUNTERBRECHUNG IN DIVERSEN AKTIENTEIL 2 () - Aktiencheck
Belite Bio (NASDAQ:BLTE) Shares Gap Up After Analyst Upgrade - Defense World
Belite Bio (NASDAQ:BLTE) Shares Gap Up Following Analyst Upgrade - MarketBeat
Benchmark Issues Positive Forecast for Belite Bio (NASDAQ:BLTE) Stock Price - Defense World
Benchmark Boosts Belite Bio (NASDAQ:BLTE) Price Target to $79.00 - MarketBeat
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):